Dolutegravir
- Generic Name
- Dolutegravir
- Brand Names
- Dovato, Juluca, Tivicay, Triumeq
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19F2N3O5
- CAS Number
- 1051375-16-6
- Unique Ingredient Identifier
- DKO1W9H7M1
- Background
Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. On Nove...
- Indication
Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at least a weight of 40 kg. The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for adults with HIV-1 in...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 11
- Registration Number
- NCT01467518
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 14
- Registration Number
- NCT01459315
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
Drug Interaction Study Between Dolutegravir and Prednisone
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 12
- Registration Number
- NCT01425099
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 183
- Registration Number
- NCT01328041
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 844
- Registration Number
- NCT01263015
- Locations
- 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom
Characterization of Acute and Recent HIV-1 Infections in Zurich.
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 800
- Registration Number
- NCT00537966
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.